The company will not receive any proceeds from the resale or other disposition of the shares of common stock by the selling stockholders.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KTTA:
- Pasithea Therapeutics prices $5M at-the-market private placement at $4.10/share
- Morning Movers: Micron and Accenture rise following quarterly results
- Pasithea Therapeutics announces initial data from Phase 1 trial of PAS-004
- Pasithea Therapeutics completes PAS-004 chronic toxicity studies
- Pasithea Therapeutics appoints Rebecca Brown to Scientific Advisory Board